What is nference?
Founded in 2013 and headquartered in Cambridge, Massachusetts, nference is dedicated to building a comprehensive software platform designed to synthesize the world's exponentially growing and siloed biomedical knowledge. The company leverages state-of-the-art neural networks for real-time, automated insight extraction. This is achieved by triangulating unstructured and structured information from the biomedical literature, as well as from large-scale molecular and real-world datasets. nference's approach aims to unlock new avenues for research and development within the life sciences sector.
Keywords: nference, biomedical knowledge platform, AI, neural networks, data extraction, biomedical literature, real-world datasets, Cambridge, Massachusetts.
How much funding has nference raised?
nference has raised a total of $131M across 3 funding rounds:
Series A
$11M
Series B
$60M
Series C
$60M
Series A (2018): $11M with participation from Matrix Partners and Matrix Capital Management
Series B (2020): $60M led by Mayo Clinic
Series C (2020): $60M supported by NTTVC, Matrix Capital Management Company, L.P., Matrix Partners, and Mayo Clinic Ventures
Key Investors in nference
Matrix Partners
Matrix Partners is a venture capital firm that has invested in nference. Their focus often includes technology and growth-stage companies.
Mayo Clinic Ventures
Mayo Clinic Ventures is the investment arm of the Mayo Clinic, focusing on healthcare innovation and companies that align with medical research and clinical practice advancements.
NTTVC
NTTVC is a venture capital firm that has participated in nference's funding rounds, likely specializing in technology and data-driven companies.
What's next for nference?
With its recent major strategic investment, nference is poised to further accelerate its mission of creating a unified biomedical knowledge graph. The substantial enterprise-level funding, totaling $131M, indicates strong investor confidence in nference's technology and its potential to revolutionize how biomedical data is accessed and utilized. This capital infusion will likely support the expansion of its platform capabilities, enhance its AI and machine learning infrastructure, and broaden its market reach. The company's focus on synthesizing complex biomedical information positions it as a key player in driving innovation in healthcare and life sciences research.
Keywords: nference, funding, investment, growth, AI, machine learning, biomedical data, healthcare innovation, life sciences, platform expansion.
